Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases

Table 1

Clinical parameters and biochemical test results for the subjects enrolled in the study.

Characteristic	Healthy controls (n=124)	CHB	LC	HCC
		(n=104)	(n=82)	(n=62)
Sex (male/female)	90/34	78/26	60/22	48/14
Age	42.2 ± 14.6	40.5 ± 12.7	47.7 ± 15.3	55.8 ± 17.5
BMI (kg/m^2)	23.5±1.4	25.3±1.6	24.7±1.5	24.4± 1.5
ALT (IU/l)	<30	206.4±283.7	52.7±76.8∗	59.9±81.5∗
AST (IU/l)	<30	146.7±200.3	65.9±65.1∗	92.7±88.6∗

n: number of subjects, CHB: chronic hepatitis B, LC: liver cirrhosis, HCC: hepatocellular carcinoma, BMI: body mass index, ALT: alanine aminotransferase, AST: aspartate aminotransferase. ∗ indicates P<0.05 compared with healthy controls.